GLPwatch
Zepbound for Polycystic ovary syndrome
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCZepbound (tirzepatide) is not FDA-approved for polycystic ovary syndrome, and any use for this condition is off-label or investigational. The listed research includes animal studies and reviews exploring tirzepatide’s effects in polycystic ovary syndrome models or related metabolic pathways, but does not provide clinical evidence of efficacy or safety in humans for this condition.
AI summary of the sources below.
| Drug | Zepbound (tirzepatide) |
|---|---|
| Condition | Polycystic ovary syndrome |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Zepbound is not FDA-approved for polycystic ovary syndrome; the research below reflects investigational or off-label study only.
Research on tirzepatide for polycystic ovary syndrome (5)
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.
- Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.